Organigram price target raised to C$6 from C$4 at Stifel » 11:3404/1504/15/21
Stifel analyst Andrew…
Stifel analyst Andrew Partheniou raised the firm's price target on Organigram to C$6 from C$4 and keeps a Hold rating on the shares.
Organigram price target lowered to C$5 from C$6 at Raymond James » 10:3904/1404/14/21
Raymond James analyst…
Raymond James analyst Rahul Sarugaser lowered the firm's price target on Organigram to C$5 from C$6 and keeps an Outperform rating on the shares.
Organigram price target raised to C$3.50 from C$2.00 at Canaccord » 07:2204/1404/14/21
Canaccord analyst Matt…
Canaccord analyst Matt Bottomley raised the firm's price target on Organigram to C$3.50 from C$2.00 and keeps a Hold rating on the shares. The analyst noted its FQ2/21 results were well under expectations as the company's continued turnaround efforts were stifled by industry wide COVID-19 pressures and provincial inventory rightsizing efforts the he believes will weigh on most Canadian LP's in the early part of 2021.
CIBC downgrades Organigram to Underperformer with C$3.25 target » 06:2704/1404/14/21
CIBC analyst John Zamparo…
CIBC analyst John Zamparo downgraded Organigram to Underperformer from Neutral with a price target of C$3.25, down from C$5. It is s difficult to foresee Organigram returning to positive EBITDA, even in fiscal 2022, due to ongoing pandemic impacts, a pause in international sales, and declining domestic market share occurring at shrinking margins, Zamparo tells investors in a research note. The analyst assumes annual sales growth of 20%, about half that of consensus estimates.
Organigram downgraded to Underperformer from Neutral at CIBC » 21:3304/1304/13/21
CIBC analyst John Zamparo…
CIBC analyst John Zamparo downgraded Organigram to Underperformer from Neutral with a C$3.25 price target.
Organigram price target lowered to C$3.75 from C$4 at Alliance Global Partners » 16:1704/1304/13/21
Alliance Global Partners…
Alliance Global Partners analyst Aaron Grey lowered the firm's price target on Organigram to C$3.75 from C$4 and keeps a Neutral rating on the shares following the company's weaker than expected fiscal Q2 results. Sales were impacted by COVID lockdowns as well as production constraints, resulting in Organigram's second quarter of sales declines, Grey tells investors in a research note. The analyst says "more tempered" near-term sales growth driving continued margin pressure keeps him on the sidelines.
|Over a week ago|
Fly Intel: Top five analyst downgrades » 09:5404/0904/09/21
CS, BTI, CHTR, ATUS, CHUY
Catch up on today's…
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Credit Suisse (CS) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Magdalena Stoklosa believing "lingering uncertainty" from the hedge fund loss will delay a re-rating in the shares. 2. British American Tobacco (BTI) downgraded to Neutral from Overweight at JPMorgan with analyst Celine Pannuti saying the company is entering an investment ramp-up phase that is likely to hold back earnings growth over the medium term. 3. Charter (CHTR) downgraded to Neutral from Buy at Citi with analyst Michael Rollins saying three recent developments give the analyst pause regarding future broadband growth for cable firms: faster annual fiber upgrades, wireless home broadband ambitions, and risks from government policy direction. 4. Altice USA (ATUS) downgraded to Neutral from Buy at Citi with analyst Michael Rollins saying consensus for average broadband net adds between 2022 and 2025 "seems too robust and may need to be cut by more than half." 5. Chuy's (CHUY) downgraded to Hold from Buy at Stifel with analyst Chris O'Cull citing valuation for the downgrade following the stock's recent rally. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
British American Tobacco downgraded to Neutral from Overweight at JPMorgan » 05:5904/0904/09/21
JPMorgan analyst Celine…
JPMorgan analyst Celine Pannuti downgraded British American Tobacco to Neutral from Overweight with a price target of 3,100 GBp, down from 3,500 GBp. Heated tobacco products are an integral part of the global nicotine industry's future and British American is still at the investment stage, Dinges tells investors in a research note. The company is entering an investment ramp-up phase that is likely to hold back earnings growth over the medium term, says the analyst.
Rising High: Canopy Growth to acquire The Supreme Cannabis Company in $435M deal » 12:0904/0804/08/21
CGC, SPRWF, OGI, AGFAF, TCNNF, VRNOF, FFNTF, PLNHF, APHA, TLRY, ACB, CVSI, CTST, CRON, CAN, IGC, ZYNE, BTI
In this week's "Rising…
Organigram upgraded to Market Perform from Underperform at BMO Capital » 20:3404/0704/07/21
BMO Capital analyst Tamy…
BMO Capital analyst Tamy Chen upgraded Organigram (OGI) to Market Perform from Underperform with an unchanged C$4.00 price target. The analyst is positive on the company's strategic collaboration with British American Tobacco (BTI), adjusting his target multiple to 10-times forward revenue from 4.5-times. Chen adds that the sector has been soft over the past few weeks, which is not surprising following the post-U.S. election rally.